TTrialPathMatch Me to Trials
← Back to trials
RecruitingFamilial Hypercholesterolemia - Heterozygous

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Eligible age

6–11 yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to \<12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).

Sponsor: Novartis Pharmaceuticals

You may qualify if…

  • ✓ Male or female participants, 6 to \<12 years of age at screening
  • ✓ HeFH diagnosed either by genetic testing or on phenotypic criteria
  • ✓ Fasting LDL-C \>130 mg/dL (3.4 mmol/L) at screening
  • ✓ For participants 8 to \<12 years, on an optimal dose of statin (investigator's discretion) unless statin intolerant, with or without other lipid-lowering therapy (e.g. ezetimibe). For participants \<8 years, the use of background lipid-lowering treatment is based on investigator's discretion.
  • ✓ Participants on lipid-lowering therapies (such as statin and/or e.g. ezetimibe) must be on a stable dose for ≥30 days before screening with no planned medication or dose changes during study participation.

You may not qualify if…

  • ✕ Previous treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9
  • ✕ Secondary hypercholesterolemia, e.g. hypothyroidism or nephrotic syndrome
  • ✕ Homozygous familial hypercholesterolemia (HoFH)
  • ✕ Body weight \<16 kg at the screening and/or randomization (Day 1) visit
  • ✕ Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST) elevation \>3x ULN, or total bilirubin elevation \>2x ULN (except patients with Gilbert's syndrome)
  • ✕ Pregnant or nursing females
  • ✕ Recent and/or planned use of other investigational medicinal products or devices

Where it's recruiting

California

San Francisco

District of Columbia

Washington D.C.

Florida

Boca Raton

New York

New York

Utah

Salt Lake City

Virginia

Richmond

West Virginia

Morgantown

Source: ClinicalTrials.gov · NCT06597019 · last updated 2026-05-15

Study to Evaluate Efficacy and Safety of Inclisiran in Children With H · TrialPath